IL17A and pustular psoriasis: In recent years, favorable results have been reported after treatment with anti-TNF agents (adalimumab, etanercept, infliximab), IL-23 inhibitors (guselkumab), phosphodiesterase-4 inhibitors (apremilast, roflumilast) and, more recently, secukinumab.3, 4, 5 We postulate that the response to this drug in our patient with SWD is explained by the role of IL-17A in neutrophil chemotaxis and the demonstrated efficacy of anti-IL-17 agents in pustular psoriasis, an entity closely related to SWD.5